Skip to content

A clinical study of Dachaihu decoction combined with low-dose compound polyethylene glycol electrolyte dispersal for bowel preparation in elderly patients with chronic constipation

A clinical study of Dachaihu decoction combined with low-dose compound polyethylene glycol electrolyte dispersal for bowel preparation in elderly patients with chronic constipation

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080157
Enrollment
Unknown
Registered
2024-01-22
Start date
2024-01-22
Completion date
Unknown
Last updated
2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic constipation

Interventions

observation group:Oral Dachaihu decoction combined with low-dose polyethylene glycol electrolyte dispersions for bowel preparation
control group:Oral polyethylene glycol electrolyte dispersions (3000 ml) for bowel preparation

Sponsors

Department of Gastroenterology, Chengdu Qingbaijiang District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged 60 and above, male or female; (2) Meet the diagnostic criteria for chronic constipation in Western medicine and Chinese medicine; (3) No other medications promoting gastrointestinal motility have been taken orally in the last 1 month; (4) The patients themselves and their families were informed about the content of this study and signed a willingness to consent form.

Exclusion criteria

Exclusion criteria: (1) a history of previous allergies to relevant medications (including Dachaihu decoction and polyethylene glycol electrolyte dispersions, dimethylsiloxane). (2) Those who are not suitable for oral administration of Da Chai Hu Tang (assessed by a Chinese medicine practitioner); (3) Unsuitable to undergo colonoscopy or belonging to the contraindications of colonoscopy (e.g., severe organic diseases of the heart, lungs, cerebrovascular, liver, kidneys, and blood system. Organic diseases of the digestive tract such as obstruction or perforation of the digestive tract, severe active inflammatory bowel disease, gastrointestinal bleeding, and massive ascites. (Those with high suspicion or clear diagnosis of malignant tumors of the digestive tract, etc.); (4) Individuals who are not suitable for colonoscopic pathology (e.g., oral antiplatelet or anticoagulant medications within 7 days, etc.); (5) Accompanied by hearing, visual, and intellectual disabilities; (6) Those who did not provide informed consent.

Design outcomes

Primary

MeasureTime frame
Boston Intestinal Preparation Scale;adverse reactio;

Secondary

MeasureTime frame
Satisfaction with colonoscopy;

Countries

China

Contacts

Public ContactLuo Rui

Chengdu Qingbaijiang District People's Hospital

525926572@qq.com+86 137 0908 8961

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026